Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression.
EMT—epithelial to mesenchymal transformation
GADD45α
maackiain
miR-374a
triple negative breast cancer
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
11
2021
accepted:
24
01
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Breast cancer ranks as the leading cause of death in lethal malignancies among women worldwide, with a sharp increase of incidence since 2008. Triple negative breast cancer (TNBC) gives rise to the largest proportion in breast cancer-related deaths because of its aggressive growth and rapid metastasis. Hence, searching for promising targets and innovative approaches is indispensable for the TNBC treatment. Maackiain (MA), a natural compound with multiple biological activities, could be isolated from different Chinese herbs, such as
Identifiants
pubmed: 35308218
doi: 10.3389/fphar.2022.806869
pii: 806869
pmc: PMC8930825
doi:
Types de publication
Journal Article
Langues
eng
Pagination
806869Informations de copyright
Copyright © 2022 Peng, Wang, Xiong, Tang, Du and Peng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurochem Res. 2018 Mar;43(3):581-590
pubmed: 29247275
Front Pharmacol. 2020 Mar 13;11:251
pubmed: 32231566
Int J Mol Sci. 2021 Sep 06;22(17):
pubmed: 34502549
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2800-2809
pubmed: 31284781
Pathol Res Pract. 2019 Jun;215(6):152382
pubmed: 30890278
Cancers (Basel). 2019 Jan 28;11(2):
pubmed: 30696076
J Clin Invest. 2013 Feb;123(2):566-79
pubmed: 23321667
PLoS One. 2013;8(2):e56631
pubmed: 23457597
Trends Biochem Sci. 2020 Feb;45(2):163-173
pubmed: 31810601
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193
pubmed: 30655609
J Biol Chem. 2013 Mar 1;288(9):6552-60
pubmed: 23329839
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Sci Data. 2019 Jul 4;6(1):113
pubmed: 31273216
Molecules. 2019 Sep 04;24(18):
pubmed: 31487934
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585871
Am J Chin Med. 2021;49(2):505-523
pubmed: 33641651
Cancer Lett. 2019 Jul 10;454:224-233
pubmed: 31004703
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188590
pubmed: 34271137
Cancer Med. 2018 May 23;:
pubmed: 29790671
Nat Prod Rep. 2021 Sep 23;38(9):1618-1633
pubmed: 33511969
Cell. 2012 Mar 16;148(6):1172-87
pubmed: 22424228
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Int J Mol Sci. 2021 Jul 14;22(14):
pubmed: 34299149
Biomed Pharmacother. 2022 Jan;145:112431
pubmed: 34798471
Oncol Rep. 2004 Dec;12(6):1183-8
pubmed: 15547735
Trends Cell Biol. 2020 Oct;30(10):764-776
pubmed: 32800658
PLoS One. 2011 Jan 07;6(1):e14500
pubmed: 21249130
J Control Release. 2021 Sep 10;337:27-58
pubmed: 34273417
FEBS J. 2020 Jul;287(14):2923-2947
pubmed: 31880863
Onco Targets Ther. 2019 Sep 16;12:7591-7599
pubmed: 31571910
Cancer Biomark. 2019;24(3):269-277
pubmed: 30883342
Sci Rep. 2017 Aug 17;7(1):8676
pubmed: 28819143
Int J Mol Sci. 2018 Sep 14;19(9):
pubmed: 30223524
Nat Rev Cancer. 2022 Jan;22(1):45-64
pubmed: 34663943
Pharmacol Res Perspect. 2015 Oct;3(5):e00166
pubmed: 26516579
Nucleic Acids Res. 2017 Jan 4;45(D1):D812-D818
pubmed: 27899556
J Exp Clin Cancer Res. 2013 Sep 19;32:69
pubmed: 24330581
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211006191
pubmed: 33884928
Front Oncol. 2021 Jul 09;11:685881
pubmed: 34307152
Oxid Med Cell Longev. 2021 Oct 6;2021:5187569
pubmed: 34659633